Brooke L Honey1, Lourdes Ramos2, Nancy C Brahm3. 1. Department of Pharmacy, Clinical and Administrative Sciences, The University of Oklahoma College of Pharmacy, Tulsa, Oklahoma ; Department of Pediatrics, The University of Oklahoma College of Medicine, Tulsa, Oklahoma. 2. Department of Pharmacy, University of Louisville Hospital, Louisville, Kentucky. 3. Department of Pharmacy, Clinical and Administrative Sciences, The University of Oklahoma College of Pharmacy, Tulsa, Oklahoma.
Abstract
OBJECTIVES: The aim of this retrospective study was to identify the frequency of recommended metabolic monitoring and follow-up in pediatric patients on second-generation antipsychotic (SGA) medications from a pediatric clinic. METHODS: A retrospective review of electronic medical records of all patients on antipsychotics from an academic medical center pediatric clinic was conducted. Inclusion criteria required patients to be established members of the pediatric clinic, < 19 years of age, and on ≥ 1 SGA for at least 1 year, regardless of medical diagnosis. Data collection consisted of patient demographic information and frequency of family history, vital signs, and recommended laboratory monitoring. RESULTS: A total of 67 patients on antipsychotics were identified. After the application of inclusion criteria, 32 patients qualified for review. The average age was 13.5 ± 4 years and gender distribution included 72% males. Only 4 (13%) patients had documented baseline monitoring that included weight, blood pressure, and fasting lipid panel. No patient had a fasting plasma glucose recorded at any point during antipsychotic therapy. Follow-up monitoring decreased over time, with the exception of quarterly weight and annual blood pressure. CONCLUSIONS: The results of this study highlight the lack of baseline and periodic monitoring that occur when pediatric patients are prescribed antipsychotic medications, putting the patient at risk for adverse events. The marked increase in antipsychotic prescribing and concerns related to their safety emphasize the need for improvement in monitoring of antipsychotic medications. This gap in patient care and safety opens an excellent opportunity for a clinical pharmacy team to provide education and assistance with SGA monitoring for the purpose of providing optimal patient care.
OBJECTIVES: The aim of this retrospective study was to identify the frequency of recommended metabolic monitoring and follow-up in pediatric patients on second-generation antipsychotic (SGA) medications from a pediatric clinic. METHODS: A retrospective review of electronic medical records of all patients on antipsychotics from an academic medical center pediatric clinic was conducted. Inclusion criteria required patients to be established members of the pediatric clinic, < 19 years of age, and on ≥ 1 SGA for at least 1 year, regardless of medical diagnosis. Data collection consisted of patient demographic information and frequency of family history, vital signs, and recommended laboratory monitoring. RESULTS: A total of 67 patients on antipsychotics were identified. After the application of inclusion criteria, 32 patients qualified for review. The average age was 13.5 ± 4 years and gender distribution included 72% males. Only 4 (13%) patients had documented baseline monitoring that included weight, blood pressure, and fasting lipid panel. No patient had a fasting plasma glucose recorded at any point during antipsychotic therapy. Follow-up monitoring decreased over time, with the exception of quarterly weight and annual blood pressure. CONCLUSIONS: The results of this study highlight the lack of baseline and periodic monitoring that occur when pediatric patients are prescribed antipsychotic medications, putting the patient at risk for adverse events. The marked increase in antipsychotic prescribing and concerns related to their safety emphasize the need for improvement in monitoring of antipsychotic medications. This gap in patient care and safety opens an excellent opportunity for a clinical pharmacy team to provide education and assistance with SGA monitoring for the purpose of providing optimal patient care.
Authors: Elaine H Morrato; Ginger E Nicol; David Maahs; Benjamin G Druss; Daniel M Hartung; Robert J Valuck; Elizabeth Campagna; John W Newcomer Journal: Arch Pediatr Adolesc Med Date: 2010-04
Authors: Susan E Andrade; Joan C Lo; Douglas Roblin; Hassan Fouayzi; Daniel F Connor; Robert B Penfold; Malini Chandra; George Reed; Jerry H Gurwitz Journal: Pediatrics Date: 2011-11-21 Impact factor: 7.124
Authors: Christoph U Correll; Jennifer Harris; Vicki Figen; John M Kane; Peter Manu Journal: J Child Adolesc Psychopharmacol Date: 2011-08-08 Impact factor: 2.576
Authors: Dan W Haupt; Lisa C Rosenblatt; Edward Kim; Ross A Baker; Richard Whitehead; John W Newcomer Journal: Am J Psychiatry Date: 2009-01-15 Impact factor: 18.112
Authors: Christoph U Correll; Peter Manu; Vladimir Olshanskiy; Barbara Napolitano; John M Kane; Anil K Malhotra Journal: JAMA Date: 2009-10-28 Impact factor: 56.272
Authors: Elaine H Morrato; Benjamin Druss; Daniel M Hartung; Robert J Valuck; Richard Allen; Elizabeth Campagna; John W Newcomer Journal: Arch Gen Psychiatry Date: 2010-01
Authors: Angie Mae Rodday; Susan K Parsons; Catherine Mankiw; Christoph U Correll; Adelaide S Robb; Bonnie T Zima; Tully S Saunders; Laurel K Leslie Journal: J Child Adolesc Psychopharmacol Date: 2015-04-28 Impact factor: 2.576
Authors: Mariken Dinnissen; Andrea Dietrich; Judith H van der Molen; Anne M Verhallen; Ynske Buiteveld; Suzanne Jongejan; Pieter W Troost; Jan K Buitelaar; Barbara J van den Hoofdakker; Pieter J Hoekstra Journal: J Clin Psychopharmacol Date: 2021 Jan/Feb 01 Impact factor: 3.118